Roche and Eli Lilly team up to support diabetes community

By Editor
11th May 2021
Pharmaceutical, Type 1 diabetes Type 2 diabetes

Two global medical organisations have teamed up to deliver a pioneering diabetes insulin therapy pen.

The world’s largest biotech company, Roche, has partnered with Eli Lilly and Company, a global leader in diabetes care, to work towards optimising the management of insulin pen therapy.

The companies will work together to integrate data from Lilly’s connected insulin pen solution into the mySugr app. The app’s worldwide users will be able to pair Lilly’s Tempo Smart Button to automatically transfer data into mySugr.

This will enable users across the globe to manage insulin pen data together with other diabetes-relevant data in one place.

By collaborating with Lilly, Roche follows its ambition to create an open ecosystem including its own and partner devices, solutions and services across the continuum of care in diabetes.

Both companies are dedicated to driving new possibilities to ease the complexity of daily decision making for people with diabetes on insulin pen therapy and their healthcare professionals.

Marcel Gmuender, Global Head of Roche Diabetes Care, said: “Lilly is a company with extensive experience in the field of insulin therapy. Together, we are looking forward to creating valuable insights into daily diabetes management and providing new opportunities for a more personalised approach in insulin pen therapy.”

Marie Schiller, vice president of product development for Connected Care and Insulins at Lilly, said: “We are thrilled to work with Roche and mySugr to advance our goal to better support the diabetes community.

“Through our collaboration, we are providing people with diabetes with more choice when it comes to their personal treatment needs and goals.”

Photo by Pixabay on Pexels.

Comments (0)

Register an account or login to comment